{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:36:58Z","timestamp":1791927418578,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88685-y","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:53:41Z","timestamp":1738558421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nonlinear associations of the hs-CRP\/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017\u20132018"],"prefix":"10.1038","volume":"15","author":[{"given":"Bin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yequan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"88685_CR1","doi-asserted-by":"publisher","first-page":"g4596","DOI":"10.1136\/bmj.g4596","volume":"349","author":"N Sattar","year":"2014","unstructured":"Sattar, N., Forrest, E. & Preiss, D. Non-alcoholic fatty liver disease. Bmj 349, g4596 (2014).","journal-title":"Bmj"},{"issue":"6","key":"88685_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79 (6), 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"issue":"4","key":"88685_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77 (4), 1335\u20131347 (2023).","journal-title":"Hepatology"},{"issue":"5","key":"88685_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64 (5), 1577\u20131586 (2016).","journal-title":"Hepatology"},{"issue":"10290","key":"88685_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397 (10290), 2212\u20132224 (2021).","journal-title":"Lancet"},{"issue":"6","key":"88685_CR6","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1016\/S1470-2045(22)00265-0","volume":"23","author":"DJH Tan","year":"2022","unstructured":"Tan, D. J. H., Ng, C. H., Muthiah, M. D., Loomba, R. & Huang, D. Q. Clinical features and outcomes of NAFLD-related hepatocellular carcinoma - authors\u2019 reply. Lancet Oncol. 23 (6), e244 (2022).","journal-title":"Lancet Oncol."},{"issue":"9","key":"88685_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69 (9), 1691\u20131705 (2020).","journal-title":"Gut"},{"issue":"7","key":"88685_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24 (7), 908\u2013922 (2018).","journal-title":"Nat. Med."},{"issue":"7","key":"88685_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jclinpath-2020-207366","volume":"75","author":"S Seth","year":"2022","unstructured":"Seth, S. et al. Audit of medical (non-targeted) liver biopsy specimen quality, pathology reporting and effect on patient management. J. Clin. Pathol. 75 (7), 498\u2013502 (2022).","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"88685_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1159\/000533328","volume":"41","author":"T Androutsakos","year":"2023","unstructured":"Androutsakos, T. et al. Liver biopsy: to do or not to do - a single-center study. Dig. Dis. 41 (6), 913\u2013921 (2023).","journal-title":"Dig. Dis."},{"issue":"3","key":"88685_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","volume":"36","author":"A Khalifa","year":"2020","unstructured":"Khalifa, A. & Rockey, D. C. The utility of liver biopsy in 2020. Curr. Opin. Gastroenterol. 36 (3), 184\u2013191 (2020).","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"1","key":"88685_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12944-024-02055-7","volume":"23","author":"Y Gao","year":"2024","unstructured":"Gao, Y. et al. The predictive value of the hs-CRP\/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study. Lipids Health Dis. 23 (1), 66 (2024).","journal-title":"Lipids Health Dis."},{"issue":"1","key":"88685_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4103\/jfmpc.jfmpc_887_19","volume":"9","author":"R Kumar","year":"2020","unstructured":"Kumar, R. et al. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian indians: a cross-sectional study. J. Family Med. Prim. Care. 9 (1), 390\u2013394 (2020).","journal-title":"J. Family Med. Prim. Care"},{"key":"88685_CR14","doi-asserted-by":"publisher","first-page":"1012887","DOI":"10.3389\/fphys.2022.1012887","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang, J., Wang, M., Wu, Y., Kumar, R. & Lin, S. Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD. Front. Physiol. 13, 1012887 (2022).","journal-title":"Front. Physiol."},{"key":"88685_CR15","doi-asserted-by":"publisher","first-page":"1246518","DOI":"10.1155\/2019\/1246518","volume":"2019","author":"Z Tang","year":"2019","unstructured":"Tang, Z. et al. Sex, Age, and BMI modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: a retrospective study on 1994 cases observed at Shuguang Hospital, China. Biomed. Res. Int. 2019, 1246518 (2019).","journal-title":"Biomed. Res. Int."},{"key":"88685_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.athplu.2023.08.001","volume":"53","author":"M Hoekstra","year":"2023","unstructured":"Hoekstra, M. & Van Eck, M. High-density lipoproteins and non-alcoholic fatty liver disease. Atheroscler Plus. 53, 33\u201341 (2023).","journal-title":"Atheroscler Plus"},{"issue":"1","key":"88685_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","volume":"19","author":"K Pu","year":"2019","unstructured":"Pu, K. et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 19 (1), 51 (2019).","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"88685_CR18","first-page":"242","volume":"7","author":"SA Hashemi","year":"2016","unstructured":"Hashemi, S. A., Alavian, S. M. & Gholami-Fesharaki, M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Casp. J. Intern. Med. 7 (4), 242\u2013252 (2016).","journal-title":"Casp. J. Intern. Med."},{"issue":"5","key":"88685_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66 (5), 1022\u20131030 (2017).","journal-title":"J. Hepatol."},{"issue":"2","key":"88685_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.30825","volume":"71","author":"RK Sterling","year":"2020","unstructured":"Sterling, R. K. et al. Evaluating noninvasive markers to identify Advanced Fibrosis by Liver Biopsy in HBV\/HIV co-infected adults. Hepatology 71 (2), 411\u2013421 (2020).","journal-title":"Hepatology"},{"key":"88685_CR21","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. (2024)."},{"issue":"22","key":"88685_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","volume":"282","author":"M Visser","year":"1999","unstructured":"Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H. & Harris, T. B. Elevated C-reactive protein levels in overweight and obese adults. Jama 282 (22), 2131\u20132135 (1999).","journal-title":"Jama"},{"issue":"9403","key":"88685_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"Appropriate body-mass","year":"2004","unstructured":"Appropriate body-mass. Index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (9403), 157\u2013163 (2004).","journal-title":"Lancet"},{"issue":"9","key":"88685_CR24","first-page":"585","volume":"42","author":"WF Rayburn","year":"1997","unstructured":"Rayburn, W. F. Diagnosis and classification of diabetes mellitus: highlights from the American Diabetes Association. J. Reprod. Med. 42 (9), 585\u2013586 (1997).","journal-title":"J. Reprod. Med."},{"key":"88685_CR25","doi-asserted-by":"crossref","unstructured":"Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L. & Tomlinson, J. W. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr. Rev. ;41(1). (2020).","DOI":"10.1210\/endrev\/bnz009"},{"issue":"4","key":"88685_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","volume":"20","author":"J Schw\u00e4rzler","year":"2024","unstructured":"Schw\u00e4rzler, J., Grabherr, F., Grander, C., Adolph, T. E. & Tilg, H. The pathophysiology of MASLD: an immunometabolic perspective. Expert Rev. Clin. Immunol. 20 (4), 375\u2013386 (2024).","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"130","key":"88685_CR27","first-page":"422","volume":"61","author":"AO Yeniova","year":"2014","unstructured":"Yeniova, A. O. et al. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease. Hepatogastroenterology 61 (130), 422\u2013425 (2014).","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"88685_CR28","doi-asserted-by":"publisher","first-page":"e49286","DOI":"10.1371\/journal.pone.0049286","volume":"8","author":"P Nigam","year":"2013","unstructured":"Nigam, P. et al. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian indians in North India. PLoS One. 8 (1), e49286 (2013).","journal-title":"PLoS One"},{"key":"88685_CR29","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan, Y. et al. Association of Inflammatory Cytokines with non-alcoholic fatty liver disease. Front. Immunol. 13, 880298 (2022).","journal-title":"Front. Immunol."},{"issue":"2","key":"88685_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","volume":"51","author":"CK Argo","year":"2009","unstructured":"Argo, C. K., Northup, P. G., Al-Osaimi, A. M. & Caldwell, S. H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51 (2), 371\u2013379 (2009).","journal-title":"J. Hepatol."},{"issue":"1","key":"88685_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12876-021-01974-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol. 21 (1), 395 (2021).","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"88685_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/0004563219853596","volume":"56","author":"J Janac","year":"2019","unstructured":"Janac, J. et al. The association between lecithin-cholesterol acyltransferase activity and fatty liver index. Ann. Clin. Biochem. 56 (5), 583\u2013592 (2019).","journal-title":"Ann. Clin. Biochem."},{"issue":"2","key":"88685_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","volume":"227","author":"AP DeFilippis","year":"2013","unstructured":"DeFilippis, A. P. et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 227 (2), 429\u2013436 (2013).","journal-title":"Atherosclerosis"},{"issue":"1","key":"88685_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13098-021-00741-5","volume":"13","author":"S Karami","year":"2021","unstructured":"Karami, S. et al. Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. Diabetol. Metab. Syndr. 13 (1), 121 (2021).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"88685_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1210\/jc.2015-3111","volume":"101","author":"F Bril","year":"2016","unstructured":"Bril, F. et al. Hepatic steatosis and insulin resistance, but not Steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J. Clin. Endocrinol. Metab. 101 (2), 644\u2013652 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"88685_CR36","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (5), 1836\u20131846 (2010).","journal-title":"Hepatology"},{"issue":"8","key":"88685_CR37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65 (8), 1038\u20131048 (2016).","journal-title":"Metabolism"},{"key":"88685_CR38","doi-asserted-by":"publisher","first-page":"212525","DOI":"10.7573\/dic.212525","volume":"7","author":"CE Kosmas","year":"2018","unstructured":"Kosmas, C. E. et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 7, 212525 (2018).","journal-title":"Drugs Context"},{"key":"88685_CR39","doi-asserted-by":"crossref","unstructured":"Zhang, L., Shi, Y., Liang, B. & Li, X. An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD. Hepatol. Commun. ;8(5). (2024).","DOI":"10.1097\/HC9.0000000000000434"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88685-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:53:47Z","timestamp":1738558427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88685"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88685-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4029"}}